A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI With the Fixed Dose Dual Combination of FF/VI, Administered Once-daily Via a Dry Powder Inhaler in Subjects With Inadequately Controlled Asthma
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Vilanterol/fluticasone furoate (Primary) ; Salbutamol; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms CAPTAIN
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 22 May 2024 Results of post hoc analysis assessing the impact of different thresholds of asthma control (ACQ - 5 scores of 1.5 less than or equal to less than or equal to 1 and less than or equal to 0.75) on a CR composite outcome in patients treated with FF/UMEC/VI and FF/VI at Week 24 and Week 52. presented at the 120th International Conference of the American Thoracic Society
- 09 Nov 2022 Results assessing the relationship between Asthma Control Questionnaire (ACQ) scores and exacerbation rates, healthcare resource utilization (HCRU), and utility values in adults with moderate-to-severe asthma presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 19 Oct 2022 Results assessing to explore potential differential treatment responses by examining asthma control (measured by the Asthma Control Questionnaire-6 [ACQ-6]) by age as a continuous variable in the CAPTAIN study, presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians.